Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, the Netherlands.
Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, INSERM, CEA, Fontenay-aux-Roses, France.
Cell. 2021 Mar 4;184(5):1188-1200.e19. doi: 10.1016/j.cell.2021.01.035. Epub 2021 Jan 26.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt personal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that prevents viral infection, transmission, and disease. Here, we present a two-component protein-based nanoparticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques. The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising vaccine candidate to curtail the SARS-CoV-2 pandemic.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）大流行继续扰乱个人生活、全球医疗保健系统和经济。因此，迫切需要一种能够预防病毒感染、传播和疾病的疫苗。在这里，我们提出了一种由两种成分的蛋白质纳米颗粒疫苗，该疫苗展示了多个 SARS-CoV-2 刺突蛋白副本。免疫研究表明，这种疫苗可在小鼠、兔子和食蟹猴中诱导出强烈的中和抗体反应。疫苗诱导的免疫可保护猕猴免受高剂量挑战，从而在上呼吸道和下呼吸道中强烈减少病毒感染和复制。这些纳米颗粒是一种有前途的疫苗候选物，可以遏制 SARS-CoV-2 大流行。
